Gennova Biopharmaceuticals Ltd., headquartered in Pune, India, is a biotechnology company dedicated to developing, producing, and commercializing biotherapeutics to address life-threatening diseases across various indications. Gennova’s socioeconomic responsibility has propelled it to establish the Global Health Initiative program, under which Gennova has established itself as a preferred research and cGMP manufacturing partner in the area of vaccine development to address some of the world’s most challenging diseases like Malaria, Leishmania, flu, etc. Gennova has developed two mRNA vaccines, GEMCOVAC®-OM and GEMCOVAC®-19, approved for Restricted Use in Emergency Situations. They are India’s first mRNA vaccines and the world’s first Thermostable mRNA vaccines against COVID-19. Further, this technology offers a rapid development path that will empower Gennova to combat future pandemic outbreaks. Gennova aspires to transform millions of people’s healthcare, primarily through technological solutions, employing AI-assisted innovation in bio-manufacturing, diagnosis, and treatment for a better outcome.